logo
Base Molecular Resonance™ Technologies Introduces Game-Changing Solution to Stop Mass Livestock Culling Amid Bird Flu Crisis

Base Molecular Resonance™ Technologies Introduces Game-Changing Solution to Stop Mass Livestock Culling Amid Bird Flu Crisis

BMRT's Revolutionary Technology Can Instantly Detect Infected Poultry, Preventing the Unnecessary Slaughter of Healthy Animals
STUART, Fla., March 13, 2025 /PRNewswire/ -- In response to the escalating crisis of mass poultry culling due to avian influenza (bird flu), Base Molecular Resonance™ Technologies (BMRT) today announced a breakthrough application of its multi-patented Base Molecular Resonance™ (BMR™) technology that can detect infected animals instantly, eliminating the need for indiscriminate mass slaughter. With this revolutionary advancement, BMRT is poised to transform disease detection in food supply chains, preserving global food security while reducing economic and environmental waste.
The Cost of Bird Flu: Financial and Agricultural Impact
Since the onset of the current avian influenza outbreak, more than 166 million birds, including chickens and turkeys, have been culled in the United States many of which were not infected. Testing data indicates that only 5-10% of these birds would have likely tested positive for the virus. In the last quarter alone, over 20 million egg-laying chickens were culled, further tightening egg supplies and driving up prices. These indiscriminate culling practices have cost poultry farmers hundreds of millions of dollars, impacting food production and straining supply chains.
As a result, egg prices have surged in response from $2.50 to $5.63, reaching as high as $12 in some areas. BMRT's technology provides an immediate and scalable solution to this crisis by enabling real-time precision-based disease detection, ensuring that only infected birds are culled while healthy flocks remain intact.
Preventing Unnecessary Livestock Loss with Precision Scanning
The current approach to containing avian influenza involves mass culling, often resulting in the destruction of millions of birds, many of them perfectly healthy. BMRT's non-invasive, instantaneous scanning technology provides an alternative that distinguishes infected birds from healthy ones in real time, preventing unnecessary destruction of food supplies while maintaining disease control.
According to Robert 'Bo' Short, BMRT Co-Founder & CEO, 'Right now, millions of chickens are being slaughtered out of fear rather than necessity. Our technology eliminates that uncertainty. With a simple scan, we can pinpoint infected animals with 100% accuracy, allowing farmers and regulators to respond with surgical precision instead of widespread devastation. This is a major step forward for global food security, animal welfare, and the agricultural economy.'
Expanding to Cattle, Pork, and Beyond
Beyond poultry, BMRT's molecular resonance technology can be adapted to detect diseases in cattle, swine, and other livestock, helping to prevent devastating outbreaks such as Mad Cow Disease, African Swine Fever, and Foot-and-Mouth Disease to name a few. With food supply disruptions becoming an increasing global concern, BMRT's cutting-edge detection capabilities have the potential to redefine safety standards across the agricultural sector.
'Bird flu is just the beginning,' added Lee Duke, BMRT Co-Founder & President. 'We can detect disease in livestock at the molecular level before symptoms even appear, allowing for rapid intervention that safeguards the food supply and protects farmers from catastrophic losses. This is the future of disease detection.'
Independently Validated for Unmatched Accuracy
BMRT's technology has been independently validated by a third-party study conducted by the Center for Applied Innovation at York St. John University in England. The landmark study confirmed BMRT's 100% accuracy in detecting gunpowder, illegal drugs, cancer and other threats in both blind and double-blind tests, with no false positives or false negatives. The same precision and reliability now apply to disease detection in the agricultural industry, making it possible to safeguard global food supplies with unprecedented efficiency.
A New Era for Agriculture and Food Security
As governments, regulatory agencies, and food producers struggle to contain the economic and ethical fallout of mass livestock culling, BMRT's solution offers a revolutionary path forward. By deploying this safe, rapid, and non-invasive screening technology, the industry can replace fear-driven responses with precision-based disease management, ensuring food stability without compromising public health.
About Base Molecular Resonance™ Technologies (BMRT)
BMRT has discovered a new area of Quantum Physics that utilizes resonant frequencies to detect particle interactions at subatomic levels. This technology, called Base Molecular Resonance™ (BMR™), can detect any compound or biological substance, including every element on the periodic table, and up to 200 cancers and other diseases. With over 20 years of prototyping and testing proving its unmatched detection capabilities, BMR™ has the potential to save millions of lives by pinpointing weapons, explosives, and other physical threats both up close and at great distances, and detecting cancers and other diseases long before they present clinical symptoms. The non-invasive, harmless, and instant scan has broad implications in cancer diagnostics, public safety, law enforcement, security, and military services.
Bryan Adams
800.522.4718 Ext. 1
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Defibrillator Market worth US$16.44 billion by 2030 with 6.5% CAGR
Defibrillator Market worth US$16.44 billion by 2030 with 6.5% CAGR

Yahoo

timean hour ago

  • Yahoo

Defibrillator Market worth US$16.44 billion by 2030 with 6.5% CAGR

DELRAY BEACH, Fla., Aug. 13, 2025 /PRNewswire/ -- The global Defibrillator Market, valued at US$11.29 billion in 2024, stood at US$11.99 billion in 2025 and is projected to advance at a resilient CAGR of 6.5% from 2025 to 2030, culminating in a forecasted valuation of US$16.44 billion by the end of the period. The growth in the defibrillator market is attributed to the increase in the prevalence of cardiovascular diseases, the increasing adult population with higher susceptibility to cardiac arrest, a strong focus of government organizations to enhance the accessibility of defibrillators by boosting the installation of public access defibrillators and providing training & programs on defibrillators. Additionally, the rapid expansion of healthcare infrastructure in emerging countries and strategic collaborations & partnerships among manufacturers to boost the new developments in defibrillators are likely to support the market's growth in the near future. Download PDF Brochure: Browse in-depth TOC on "Defibrillator Market" 337 - Tables57 - Figures296 - Pages By product, the defibrillators market is broadly segmented into implantable cardioverter defibrillators (ICDs) and external defibrillators. The implantable cardioverter defibrillators (ICDs) segment is anticipated to capture the largest global defibrillator market share by product in 2024. Timely intervention using implantable defibrillators during cardiac emergencies is a key advantage offered by this programmed device. Moreover, growing approvals of technologically advanced implantable defibrillators and rising preference for subcutaneous ICDs are likely to support the growth of this segment during the forecast period. By end users, the defibrillators market is segmented into Hospitals & Clinics, Cardiac Centers, Pre-hospital Settings, Public-Access Markets, Home Care Settings, and Other End Users. The hospitals & clinics segment dominated the global defibrillators market in 2024. The significant rise in hospitalization for critical cardiac conditions, the growing number of ICD and CRT-D implant procedures performed in hospitals, and the rising prevalence of cardiac diseases among geriatric patients are the major factors boosting the demand for defibrillators among target end-user segments during the study period. By geography, the defibrillator market is segmented based on the region into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for the largest share of the defibrillator market. This can be attributed to the rapid adoption of technologically advanced defibrillators, favorable reimbursement policy, and the strong presence of manufacturers with a strong focus on strengthening R&D through investments in new product development. Asia Pacific is expected to grow at the highest CAGR during the forecast period owing to the presence of a large target patient pool, government initiatives to modernize & expand healthcare infrastructure, and expansion of market players in the region. Request Sample Pages : Major players in the defibrillator market include Medtronic (Ireland), Stryker (US), Koninklijke Philips N.V. (Netherlands), Asahi Kasei Corporation (Japan), Boston Scientific Corporation (US), Abbott (US), MicroPort Scientific Corporation (China), Nihon Kohden Corporation (Japan), Biotronik (Germany), and CU Medical Systems, Inc. (South Korea). MEDTRONIC: MEDTRONIC Due to its extensive product portfolio, Medtronic is the leading player in the global implantable defibrillator market. The company primarily focuses on developing innovative products to treat and manage heart failure and heart rhythm disorders. The company focuses on inorganic business growth strategies such as product development & commercialization, acquisitions, and market expansions to strengthen its current position and gain a larger share of the neurovascular devices market. The company received the CE Mark for its implantable defibrillator systems, Aurora EV-ICD MRI SureScan and Epsila EV MRI SureScan for managing irregular heart rhythms. Moreover, the company is also focusing on expanding its R&D capabilities to fuel product development and commercialization across mature and emerging markets. Koninklijke Philips N.V. Koninklijke Philips N.V. is a key player in the global defibrillator market, driven by its widely adopted HeartStart AED series. The company has established a strong presence through user-friendly, reliable devices designed for both public and professional use. Philips continues to lead with innovations such as real-time guidance, fast shock delivery, and connected care capabilities. Its strategic focus on accessibility, digital integration, and global deployment has reinforced its role in advancing out-of-hospital cardiac care. Boston Scientific Corporation Boston Scientific Corporation focuses on innovation and product launches in cardiac rhythm management to provide advanced solutions to healthcare professionals to improve the quality of life. The company continuously invests in R&D to launch new & innovative products. Boston Scientific primarily pursues the strategy of new product launches to sustain its position in the global defibrillators market. Regulatory approvals for its MRI-compatible defibrillators and technological advancements are expected to help the company maintain its position in the market. For more information, Inquire Now! Related Reports: Refurbished Medical Equipment Market IoT Medical Devices Market Cardiac Monitoring & Cardiac Rhythm Management Devices Market Respiratory Care Devices Market Top 10 Medical Device Technologies Market Get access to the latest updates on Defibrillator Companies and Defibrillator Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets

InventHelp Inventor Develops Organic Formula to Reduce Pain (HWT-601)
InventHelp Inventor Develops Organic Formula to Reduce Pain (HWT-601)

Yahoo

time2 hours ago

  • Yahoo

InventHelp Inventor Develops Organic Formula to Reduce Pain (HWT-601)

PITTSBURGH, Aug. 13, 2025 /PRNewswire/ -- "I thought there could be an all-organic formula to assist with pain relief and stiffness in various areas of the body," said an inventor, from Rock Creek, Ohio, "so I invented the PAIN AWAY. My formula works quickly to reduce pain, inflammation, and discomfort." The patent-pending invention provides an all-organic formula to aid in the treatment of pain caused by various ailments such as arthritis, back pain, restless leg syndrome, etc. In doing so, it helps relieve pain and discomfort. It also could increase mobility. The invention features an effective formula that is easy to apply so it is ideal for individuals with arthritis, back pain, etc. The original design was submitted to the National sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 24-HWT-601, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at View original content to download multimedia: SOURCE InventHelp

Seek Labs Unveils Investigational, Equipment-Free Molecular Prototype for MTB on Rapid-Deploy SeekIt™ Platform
Seek Labs Unveils Investigational, Equipment-Free Molecular Prototype for MTB on Rapid-Deploy SeekIt™ Platform

Business Wire

time2 hours ago

  • Business Wire

Seek Labs Unveils Investigational, Equipment-Free Molecular Prototype for MTB on Rapid-Deploy SeekIt™ Platform

SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced a significant advancement in the global fight against tuberculosis (TB) with an investigational prototype for Mycobacterium tuberculosis (MTB) detection on its SeekIt™ platform. In internal analytical testing, the MTB SeekIt test delivered accurate results in under 60 minutes. Importantly, this innovation addresses a key limitation that has historically hindered effective TB diagnostics: breaking apart MTB's waxy, lipid-rich cell wall to gain access to detectable genetic material. In internal testing, SeekIt's proprietary chemical lysis step achieved this in just 15 minutes without heat, mechanical disruption, or complex lab tools and skilled operators. Seek Labs achieved a functional investigational prototype in one quarter by leveraging its suite of in-house, pre-validated diagnostic technologies, focusing new innovation efforts on the MTB-specific lysis step. Share Seek Lab's MTB test demonstrates the speed, adaptability, and field-readiness of the modular SeekIt platform. All SeekIt's components—lysis chemistry, extraction, amplification, and detection—are proprietary to Seek Labs, exclusively discovered and developed in-house, and have been internally validated for performance and integration across multiple applications. The Global TB Testing Gap TB kills more than 1.25 million people each year, with nearly one in three cases going undiagnosed. In high-burden, resource-limited settings, centralized molecular tests face major hurdles: Pathogen complexity: MTB's waxy, lipid-rich cell wall has proven intractable to portable lysis methods for decades. Infrastructure dependence: Gold-standard molecular tests require expensive, power-intensive instruments, refrigeration, and highly skilled (or trained) operators. Sample limitations: Sputum collection is challenging for many patients and can deter testing. 'TB diagnostics have long been limited by gaps in both infrastructure and innovation that have often meant severe consequences for patient care and public health,' said Jared Bauer, CEO of Seek Labs. 'Our rapid, point-of-care SeekIt MTB test is designed to enable molecular-level detection in settings where access to equipment and electricity may be limited.' From Sample to Result: A Simplified Workflow At the core of the MTB SeekIt test is a proprietary, single-step chemical lysis buffer, involving a specially-formulated solution that disrupts MTB cells to release their genomic DNA. This breakthrough innovation takes just 15 minutes at room temperature, while competing methods (high-heat incubation or mechanical bead-beating) require longer times plus expensive equipment, specialized technicians, and complex infrastructure. More importantly, the integrated SeekIt test means the lysate itself flows seamlessly into SeekIt's downstream test components: Seek Extraction™ — A proprietary membrane-based binding system, developed and validated by Seek Labs, that rapidly captures MTB DNA without lab instruments. In validation testing, the MTB DNA yield for Seek Extraction was consistently more than 70% when compared to leading spin-column kits. Seek Amplification™ — A proprietary process that exponentially copies DNA at a constant temperature, detecting as few as 10 MTB genomic copies in 30 minutes without thermal cycling (internally validated), the conventional lab-based method. Molecular Lateral Flow Assay (mLFA) — A test strip that delivers clear, visual results in minutes indicating the presence of amplified DNA in a manner that can be optionally paired with the SeekIt mobile app for digital analysis and connectivity. Speed as a Strategy Conventional development of a molecular test for MTB can take a year or more. Seek Labs achieved a functional investigational prototype in one quarter by leveraging its suite of in-house, pre-validated diagnostic technologies, focusing new innovation efforts on the MTB-specific lysis step. This rapid-deployment approach illustrates how SeekIt can be rapidly developed for numerous high-priority diseases in record time. 'This was more than a fast project; it's proof of our platform's flexibility,' said Kim Wirthlin, Chief Strategy Officer. 'By focusing our innovation on the MTB-specific lysis step for compatibility with our downstream isothermal amplification, we solved one of TB diagnostics' toughest technical challenges and produced a functional investigational prototype in a single quarter.' From Conference to Collaboration Seek Labs will debut the MTB SeekIt prototype at the 2025 Next Generation Dx Conference (August 18–20, 2025, Washington, D.C.), including: Podium Presentation — Enabling Point of Care Diagnostics Track, Tuesday, August 19 at 10:00 AM ET. Scientific Poster — Detailing the proprietary lysis chemistry, rapid development process, and validation data. Seek Labs is actively seeking partners across global health (ministries of health, TB-focused NGOs, and diagnostics distributors in high-burden regions such as sub-Saharan Africa and Southeast Asia) to advance the MTB SeekIt test through clinical validation, regulatory approval, and deployment. 'Innovation means nothing if it doesn't reach people,' said Bauer. 'We want to work with those who share our vision to advance development of accurate, accessible TB testing solutions wherever they're needed most.' About Seek Labs At Seek Labs, we don't wait for change—we build it. We're pursuing the breakthroughs the world can't wait for by developing programmable 'seek-and-destroy' therapeutics and point-of-care molecular diagnostics that close the gap between outbreak and intervention. At the core of this mission is a layered architecture: BioSeeker™ serves as the Intelligence Layer, continuously mapping conserved viral vulnerabilities in real time; these insights activate our Deployment Layers (PTAP™ for programmable therapeutics and SeekIt™ for molecular diagnostics), forming a full-stack development engine designed to accelerate response, innovation, and impact across global health. Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah's collaborative life sciences ecosystem. Together with our partners, we're building faster, smarter solutions for the world's most urgent health challenges. Forward-Looking Statements and Regulatory Disclaimer This press release contains forward-looking statements, including statements regarding development timelines, clinical validation, regulatory pathways, and potential collaborations. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties—including scientific, regulatory, manufacturing, clinical, and commercial risks—that could cause actual results to differ materially. The MTB SeekIt assay is an investigational device. Limited by Federal law to investigational use.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store